Literature DB >> 1540608

Vascular (humoral) rejection in human cardiac allograft biopsies: relation to circulating anti-HLA antibodies.

R Cherry1, H Nielsen, E Reed, K Reemtsma, N Suciu-Foca, C C Marboe.   

Abstract

Vascular or humoral rejection (as defined by linear deposits of immunoglobulin and complement in myocardial capillaries) and the presence of circulating lymphocytotoxic anti-HLA antibodies are each associated with reduced long-term graft or patient survival. The relationship between these two factors has not been determined. We used immunofluorescent techniques to study 46 cardiac biopsy specimens in 16 patients from 15 to 412 days after transplantation. Biopsy specimens were selected from the first 2 months, and at approximately 6 and 12 months after transplantation and did not include episodes of acute cellular rejection. Each specimen studied was compared to a serum sample drawn an average of 1.8 days (range, 0 to 9 days) from the time of biopsy to assay for circulating anti-HLA antibodies. Of the specimens obtained at or near a positive anti-HLA antibody test, 90% (27 of 30) were found to have linear deposits of immunoglobulin (not necessarily with complement) versus 75% (12 of 16) of specimens obtained at the time of a negative test. Twenty-one cases of vascular rejection were documented. Both immunoglobulin M and immunoglobulin G were deposited along with complement in 13 instances; immunoglobulin M and complement were deposited in eight cases; no case had only immunoglobulin G and complement. The presence of circulating anti-HLA antibody in the serum was associated with 14 of the 21 cases of vascular rejection. Linear deposits of immunoglobulin in the capillaries of myocardium were frequently observed when anti-HLA antibodies were present in the serum.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1540608

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  10 in total

1.  Antibody-mediated rejection in human cardiac allografts: evaluation of immunoglobulins and complement activation products C4d and C3d as markers.

Authors:  E R Rodriguez; Diane V Skojec; Carmela D Tan; Andrea A Zachary; Edward K Kasper; John V Conte; William M Baldwin
Journal:  Am J Transplant       Date:  2005-11       Impact factor: 8.086

Review 2.  Human leukocyte antigen antibodies for monitoring transplant patients.

Authors:  Junchao Cai; Paul I Terasaki
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

3.  Alloantibody and complement promote T cell-mediated cardiac allograft vasculopathy through noncanonical nuclear factor-κB signaling in endothelial cells.

Authors:  Dan Jane-Wit; Thomas D Manes; Tai Yi; Lingfeng Qin; Pamela Clark; Nancy C Kirkiles-Smith; Parwiz Abrahimi; Julie Devalliere; Gilbert Moeckel; Sanjay Kulkarni; George Tellides; Jordan S Pober
Journal:  Circulation       Date:  2013-09-17       Impact factor: 29.690

Review 4.  Management of allosensitized cardiac transplant candidates.

Authors:  Mauricio Velez; Maryl R Johnson
Journal:  Transplant Rev (Orlando)       Date:  2009-10       Impact factor: 3.943

Review 5.  Coronary cardiac allograft vasculopathy versus native atherosclerosis: difficulties in classification.

Authors:  Annalisa Angelini; Chiara Castellani; Marny Fedrigo; Onno J de Boer; Lorine B Meijer-Jorna; Xiaofei Li; Marialuisa Valente; Gaetano Thiene; Allard C van der Wal
Journal:  Virchows Arch       Date:  2014-05-08       Impact factor: 4.064

6.  Unexplained Graft Dysfunction after Heart Transplantation-Role of Novel Molecular Expression Test Score and QTc-Interval: A Case Report.

Authors:  Khurram Shahzad; Martin Cadeiras; Kotaro Arai; Dmitry Abramov; Elizabeth Burke; Mario C Deng
Journal:  Cardiol Res Pract       Date:  2010-06-22       Impact factor: 1.866

7.  Plasma Exchange and Immunoadsorption of Patients with Thoracic Organ Transplantation.

Authors:  Silke Rummler; Dagmar Barz
Journal:  Transfus Med Hemother       Date:  2012-07-20       Impact factor: 3.747

8.  Percutaneous transluminal coronary angioplasty of focal coronary lesions after cardiac transplantation.

Authors:  W von Scheidt; B M Kemkes; B Reichart; E Erdmann
Journal:  Clin Investig       Date:  1993-07

9.  Immune responses to self-antigens (autoimmunity) in allograft rejection.

Authors:  Sabarinathan Ramachandran; Vijay Subramanian; Thalachallour Mohanakumar
Journal:  Clin Transpl       Date:  2012

Review 10.  Immune-mediated vascular injury and dysfunction in transplant arteriosclerosis.

Authors:  Anna von Rossum; Ismail Laher; Jonathan C Choy
Journal:  Front Immunol       Date:  2015-01-12       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.